Guanhao Biotech Co.,Ltd. (SHE:300238)
China · Delayed Price · Currency is CNY 15.65
+0.04 (0.26%)
Feb 13, 2026, 3:04 PM CST
Guanhao Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 378.86 | 363.52 | 388.8 | 361.02 | 462.6 | 415.21 |
Other Revenue | 13.97 | 13.97 | 15.38 | 16.27 | 26.38 | 21.75 |
| 392.83 | 377.48 | 404.18 | 377.29 | 488.98 | 436.96 | |
Revenue Growth (YoY) | 5.21% | -6.60% | 7.13% | -22.84% | 11.91% | -0.21% |
Cost of Revenue | 84.87 | 78.83 | 88.26 | 159.6 | 125.38 | 125.09 |
Gross Profit | 307.95 | 298.65 | 315.92 | 217.69 | 363.6 | 311.87 |
Selling, General & Admin | 218.25 | 214.63 | 221.9 | 210.31 | 242.05 | 230.62 |
Research & Development | 34.31 | 36.16 | 44.5 | 50.52 | 46.62 | 34.25 |
Other Operating Expenses | 13.54 | 4.04 | 3.15 | 3.03 | 4.07 | 2.8 |
Operating Expenses | 269.26 | 263.39 | 276.27 | 272.77 | 295.44 | 270.33 |
Operating Income | 38.69 | 35.26 | 39.65 | -55.08 | 68.16 | 41.54 |
Interest Expense | -3.38 | -1.03 | -1.78 | -4.11 | -7.36 | -14.58 |
Interest & Investment Income | 0.65 | 1.27 | 1.5 | 2.22 | 2.19 | 3.22 |
Currency Exchange Gain (Loss) | -0.12 | -0.12 | -3.52 | -2.34 | 0.58 | 1.69 |
Other Non Operating Income (Expenses) | 0.69 | 0.24 | -4.11 | 1.11 | -5.8 | -2.81 |
EBT Excluding Unusual Items | 36.53 | 35.62 | 31.74 | -58.2 | 57.77 | 29.07 |
Impairment of Goodwill | - | - | - | -214.33 | -0.15 | - |
Gain (Loss) on Sale of Investments | -10.84 | -10.84 | -3.64 | -41.36 | -4.68 | -3.14 |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0.92 | 0.03 | 0.33 | -0.01 |
Asset Writedown | -6.59 | -4.98 | -0.29 | -3.61 | -0.05 | -0.04 |
Other Unusual Items | 9.68 | 8.19 | 3.35 | 24.9 | 28.83 | 19 |
Pretax Income | 28.8 | 28.02 | 32.09 | -292.58 | 82.06 | 44.88 |
Income Tax Expense | 12.43 | 11.41 | 11.02 | 35.06 | 31.32 | 3.52 |
Earnings From Continuing Operations | 16.38 | 16.61 | 21.07 | -327.64 | 50.74 | 41.36 |
Minority Interest in Earnings | 9.92 | 10.81 | 9.93 | 19.81 | 22.95 | 5.23 |
Net Income | 26.3 | 27.42 | 31.01 | -307.82 | 73.69 | 46.59 |
Net Income to Common | 26.3 | 27.42 | 31.01 | -307.82 | 73.69 | 46.59 |
Net Income Growth | 49.68% | -11.58% | - | - | 58.14% | - |
Shares Outstanding (Basic) | 266 | 274 | 258 | 265 | 263 | 259 |
Shares Outstanding (Diluted) | 266 | 274 | 258 | 265 | 263 | 259 |
Shares Change (YoY) | -2.89% | 6.11% | -2.63% | 0.83% | 1.66% | -2.65% |
EPS (Basic) | 0.10 | 0.10 | 0.12 | -1.16 | 0.28 | 0.18 |
EPS (Diluted) | 0.10 | 0.10 | 0.12 | -1.16 | 0.28 | 0.18 |
EPS Growth | 54.13% | -16.67% | - | - | 55.56% | - |
Free Cash Flow | 17.99 | -26.65 | 0.23 | 29.81 | 117.68 | 100.94 |
Free Cash Flow Per Share | 0.07 | -0.10 | 0.00 | 0.11 | 0.45 | 0.39 |
Gross Margin | 78.39% | 79.12% | 78.16% | 57.70% | 74.36% | 71.37% |
Operating Margin | 9.85% | 9.34% | 9.81% | -14.60% | 13.94% | 9.51% |
Profit Margin | 6.69% | 7.26% | 7.67% | -81.59% | 15.07% | 10.66% |
Free Cash Flow Margin | 4.58% | -7.06% | 0.06% | 7.90% | 24.07% | 23.10% |
EBITDA | 58.16 | 55.6 | 61.16 | -31.56 | 94.51 | 69.72 |
EBITDA Margin | 14.80% | 14.73% | 15.13% | -8.37% | 19.33% | 15.96% |
D&A For EBITDA | 19.46 | 20.34 | 21.51 | 23.52 | 26.35 | 28.18 |
EBIT | 38.69 | 35.26 | 39.65 | -55.08 | 68.16 | 41.54 |
EBIT Margin | 9.85% | 9.34% | 9.81% | -14.60% | 13.94% | 9.51% |
Effective Tax Rate | 43.14% | 40.73% | 34.33% | - | 38.17% | 7.83% |
Revenue as Reported | 392.83 | 377.48 | 404.18 | 377.29 | 488.98 | 436.96 |
Advertising Expenses | - | 10.97 | 12.39 | 9.43 | 15.72 | 8.6 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.